What question did this study set out to answer?

March 13, 2026Open Access

Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis

Key Points

To evaluate the effects of ocrelizumab on paramagnetic rim lesions in multiple sclerosis patients.
Conducted a longitudinal study involving 29 patients treated with ocrelizumab
Identified 97 paramagnetic rim lesions using quantitative susceptibility mapping
Compared QSM values of PRLs before and after treatment
PRLs had significantly higher QSM values than non-PRLs before treatment (p = 0.001)
After treatment, PRLs showed a greater reduction in QSM values (p < 0.001)
Indicated an accelerated decline in susceptibility in PRLs post-therapy

Abstract

Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron-laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on PRLs remains unclear. In a longitudinal study of 29 ocrelizumab-treated patients with at least one PRL on quantitative susceptibility mapping (QSM), 97 PRLs were identified. Before treatment, PRLs showed higher QSM values than non-PRLs (p = 0.001), indicating iron enrichment. After treatment, PRLs demonstrated a greater QSM reduction (p < 0.001), with an accelerated decline in susceptibility. These findings suggest ocrelizumab may attenuate iron-related inflammation in PRLs.

Read Full Paperexternally

AI से पूछें

Bookmark

View Full Paper